FWBI vs. IPA, BOLT, QLI, NNVC, ENLV, JAN, BIVI, RNXT, VIRX, and BCTX
Should you be buying First Wave BioPharma stock or one of its competitors? The main competitors of First Wave BioPharma include ImmunoPrecise Antibodies (IPA), Bolt Biotherapeutics (BOLT), Qilian International Holding Group (QLI), NanoViricides (NNVC), Enlivex Therapeutics (ENLV), JanOne (JAN), BioVie (BIVI), RenovoRx (RNXT), Viracta Therapeutics (VIRX), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
ImmunoPrecise Antibodies (NASDAQ:IPA) and First Wave BioPharma (NASDAQ:FWBI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
First Wave BioPharma has lower revenue, but higher earnings than ImmunoPrecise Antibodies.
First Wave BioPharma received 3 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 45.45% of users gave First Wave BioPharma an outperform vote.
ImmunoPrecise Antibodies currently has a consensus price target of $7.00, suggesting a potential upside of 525.00%. First Wave BioPharma has a consensus price target of $36.00, suggesting a potential upside of ∞. Given ImmunoPrecise Antibodies' higher possible upside, analysts clearly believe First Wave BioPharma is more favorable than ImmunoPrecise Antibodies.
6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 12.3% of First Wave BioPharma shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 0.5% of First Wave BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, ImmunoPrecise Antibodies and ImmunoPrecise Antibodies both had 1 articles in the media. First Wave BioPharma's average media sentiment score of 1.88 beat ImmunoPrecise Antibodies' score of 1.87 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.
First Wave BioPharma has a net margin of 0.00% compared to First Wave BioPharma's net margin of -60.23%. First Wave BioPharma's return on equity of -26.54% beat ImmunoPrecise Antibodies' return on equity.
ImmunoPrecise Antibodies has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, First Wave BioPharma has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Summary
ImmunoPrecise Antibodies beats First Wave BioPharma on 8 of the 14 factors compared between the two stocks.
Get First Wave BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for FWBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FWBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
First Wave BioPharma Competitors List
Related Companies and Tools
